Compare Garmin Ltd. (GRMN) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Garmin Ltd. trades at $268.37 (market cap $51.77B), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: Garmin Ltd. is far larger — about 4.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Garmin Ltd. pays a 1.56% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| GRMN | HALO | |
|---|---|---|
Market Cap | $51.77B | $12.58B |
Volume | 961,398 | 2,179,278 |
Sector | Technology | Health |
52-Week High | $313.16 | $115.22 |
52-Week Low | $187.10 | $61.63 |
Typical Hold Time | 83 Days | 1 Days |
Enterprise Value | $49.28B | $14.49B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.36, down 2.82% on the day, reflecting a recent bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 expectation. Revenue and net income have shown steady growth, reaching $7.25 billion and $1.66 billion respectively in 2025. Positive news includes product awards and new feature rollouts, yet analyst consensus remains heavily weighted toward Hold.
The outlook balances robust profitability and growth against a cautious Wall Street sentiment and near-term technical weakness. Investment opportunity lies in the company's strong execution and product innovation, but risks include competitive pressures and market volatility. The consensus price target of $320.25 suggests significant potential upside from the current price if positive earnings trends continue.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
